A case–control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression by Chang, Cindy M. et al.
A case-control study of tobacco use and other non-occupational
risk factors for lymphoma subtypes defined by t(14;18)
translocations and bcl-2 expression
Cindy M. Chang1, Jane C. Schroeder2, Andrew F. Olshan2, Cherie H. Dunphy3, Wen-Yi
Huang4, Ralph S. Baric2, Kathleen Conway2, James R. Cerhan5, Charles F. Lynch6,
Nathaniel Rothman4, Kenneth P. Cantor4, and Aaron Blair4
1Infections and Immunoepidemiology Branch, National Cancer Institute, Rockville, MD
2Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill,
Chapel Hill, NC
3Department of Pathology and Laboratory Medicine, School of Medicine, University of North
Carolina at Chapel Hill, Chapel Hill, NC
4Occupational and Environmental Epidemiology Branch, National Cancer Institute, Bethesda, MD
5Health Sciences Research, Mayo Clinic, Rochester, MN
6Department of Epidemiology, University of Iowa, Iowa City, IA
Abstract
Objective—We re-evaluated reported associations between tobacco use and other factors and
non-Hodgkin lymphoma (NHL) t(14;18)-subtypes based on fluorescence in situ hybridization
(FISH) assays believed to be more sensitive than polymerase chain reaction (PCR), previously
used for detecting t(14;18).
Methods—Commercial FISH assays and bcl-2 immunostaining were performed on paraffin
sections to determine t(14;18) and bcl-2 case-subtypes. Polytomous logistic regression models
estimated associations between NHL case-subtypes (versus 1,245 population-based controls) and
tobacco use as well as other factors.
Results—Adjusting for age, state, and proxy status, t(14;18)-negative NHL was associated with
any tobacco use (vs. no tobacco use, OR=1.9, 95% CI=1.0-3.5), including current smoking (vs. no
cigarette use, OR= 1.9, 95% CI=1.1-3.2). Tobacco exposures were not clearly associated with
t(14;18)-positive NHL or bcl-2 case-subtypes. Hair dye use and family history of a
hemolymphatic cancer were associated with t(14;18)-negative NHL, but the number of exposed
cases was small.
Conclusions—The association between t(14;18)-negative NHL and cigarette smoking was
unexpected given previous evidence of associations between smoking and follicular lymphoma
(which is largely t(14;18)-positive). Future studies characterizing additional molecular
characteristics of t(14;18)-negative NHL may help determine whether the association with
smoking may have been causal versus an artifact of chance or bias.
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It has been suggested that associations observed between follicular lymphoma and smoking
may reflect an effect of smoking on the frequency or prevalence of t(14;18)-positive
lymphocytes which results in the overexpression of the antiapoptic protein bcl-2 (1). A
previous analysis in which polymerase chain reaction (PCR) assays were run to detect
t(14;18) in archival tumor samples from a subset of Iowa and Minnesota NHL cases in the
Factors Affecting Rural Men (FARM) case-control study (2) did not find a clear association
between smoking and t(14;18)-NHL case-subtypes, but nondifferential misclassification of
cases may have occurred. Although PCR is believed to be a reasonably specific method for
detecting t(14;18) in archival tumor samples, sensitivity is limited because assays fail to
detect translocations with BCL2 breakpoints that occur outside of regions bounded by the
PCR primers used. Consequently, approximately 15-25% of t(14;18)-positive cases may be
misclassified as t(14;18)-negative based on PCR [3].
In contrast, fluorescence in situ hybridization (FISH) assays can detect translocations with
more widely dispersed breakpoints than PCR. Studies comparing t(14;18) assays run on the
same samples have shown that FISH consistently detects more t(14;18)-positive samples
than PCR (3-8). In addition, use of FISH allows in situ localization of t(14;18) to neoplastic
lymphocytes, thus decreasing the likelihood of falsely classifying lymphomas as t(14;18)-
positive due to amplification of rare non-neoplastic t(14;18)-positive lymphocytes (9-11).
Therefore, we re-evaluated associations between t(14;18)-positive and –negative case
subtypes and tobacco use, family history and other factors among FARM study participants
after using FISH assays to re-classify the t(14;18) status of archival tumor samples that were
previously classified based on PCR (2). In order clarify whether associations may be due to
t(14;18) or bcl-2 expression which can be caused by multiple mechanisms (12), we
estimated associations with lymphoma subtypes defined by bcl-2 expression based on
immunohistochemistry.
Materials and methods
Study population and exposure assessment
The FARM study is a population-based study of incident, pathologically confirmed
hemolymphatic cancer cases in Iowa and Minnesota men that was designed to evaluate the
possible role of agricultural factors in the origin of NHL. The study population and methods
were previously described in detail (13-14). Briefly, cases and controls were white male
residents of Iowa or non-metropolitan areas of Minnesota. Cases diagnosed with a
hemolymphatic cancer between 1980 and 1983 at age 30 or older were identified through
hospital and pathology laboratory records (in Minnesota) and the Iowa State Health
Registry. NHL was confirmed for 622 cases based on pathology review. Controls, identified
using random digit dialing, Medicare files, and death certificate files, included 1,245 white
males without a history of hemolymphatic cancer who were age 30 or older at enrollment.
Controls were frequency-matched to cases by age and state. In addition, cases and controls
were frequency matched on vital status, so that study interviews with next-of-kin proxies
were conducted for one-third of cases and controls. Detailed information including past or
current tobacco use, type, frequency and duration was obtained through in-person structured
interviews administered between 1981 and 1984. Response rates were 86% for cases and
77-79% for controls.
Case-subtypes
Archival paraffin-embedded tumor blocks were successfully retrieved for 248 FARM study
NHL cases (40% of all NHL cases in the original study) (2). Based on pathology review of
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the 10-micron sections cut from archival tumor blocks, cases were classified based on the
Revised European American Lymphoma (REAL) classification scheme (15). For the present
study we describe case subtypes using updated terminology that is generally consistent with
the current WHO lymphoma classification scheme (16-17).
The methods for the PCR, FISH, and bcl-2 immunostaining have been previously described
in detail (2,16). In brief, the t(14;18)-PCR assays were performed on DNA extracted from
10-micron tumor sections using a consensus primer corresponding to a conserved portion of
the J segment of the IGH gene on chromosome 14 (5′-ACCTGAGGAGACGGTGAGC-3′)
and a second primer corresponding to the BCL2 major breakpoint region (MBR) on
chromosome 18 (MBR1: 5′-GAGAGTTGCTTTACGTG-GCCTG-3′) which includes
40-60% of BCL2 breakpoints involved in t(14;18). Translocation-negative samples were
subjected to a second PCR reaction with the IGH consensus primer and a second BCL2
primer 360 base pairs upstream of the MBR primer (MBR2: 5′-
CGCTTGACTCCTTTACGTGCTG-3′). Amplification was confirmed using radio-labeled
probes that hybridized to DNA adjacent to each BCL2 primer site. Amplification of a 175-
base pair segment of the hemoglobin beta (HBB) gene served as an internal positive control.
Commercially available FISH t(14;18) assays were run on 5-micron tumor sections stored at
4°C prior to use (Vysis/Abbot Molecular, Des Plaines, IL). t(14;18) translocations were
identified using the LSI® IGH/BCL2 Dual Color, Dual Fusion Translocation Probe. t(14;18)
assays were scored by two investigators on 166 cases (16). Cases were classified as
translocation-positive if more than 30% of cells showed abnormal signal patterns.
Preconsensus concordance was 73% for FISH (including unreadable cases). Samples with
discordant results were assigned a consensus classification based on a joint review.
bcl-2 immunostaining was performed on tumor sections from 229 cases using a mouse
monoclonal antibody corresponding to bcl-2 amino acids 41-54 (clone 124; Dako Denmark
A/S, Copenhagen, Denmark). Scored by two investigators, cases were classified as bcl-2
positive if more than 20% of cells showed cytoplasmic staining. Preconsensus concordance
was 92% for bcl-2, and discordant cases were reviewed and assigned a consensus
classification.
Data analysis
Analyses including models for case-subtypes were performed using data from 227 cases
with complete FISH, PCR, and immunostaining data. Use of any tobacco and specific
tobacco products (cigarettes, cigars, pipe tobacco, chewing tobacco, snuff) was defined as
daily use for at least 3 months. Cigarette smoking was categorized according to past
(stopped more than 2 years before interview) or current smoking (within 2 years of
interview), average intensity of use (0, 1-10, 11-20, >20 cigarettes per day), age of first use
(18 or less, over age 18), and pack-years (0, >0-20, >20-40, >40). In addition, we estimated
associations between NHL case-subtypes and other putative NHL risk factors including,
family history of hemolymphatic cancer (in a first- or second-degree relative), hair dye use
(at least once a month for at least one year, or occupational exposure to hair dyes on any job
held for 1 or more years), occupation as farmer (worked on a farm for 6 continuous months
or longer since the age 18), weekly alcohol use (drank beer, wine or hard liquor weekly for
at least one year), education (<=12 years, >12 years), and marital status (married/widowed,
divorced/separated, never married).
Case-only (case-case) analyses were performed to determine whether estimates were
comparable between molecular subtypes, including t(14;18)-positive vs. –negative case-
subtypes and bcl-2 positive vs. -negative case-subtypes using unconditional logistic
regression models (SAS® version 9.1) (18). Case-subtype: control associations were
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estimated by polytomous logistic regression models with the expectation-maximization
(EM) algorithm used to reduce potential bias caused by missing case-subtype data (for cases
for whom tumor blocks could not be retrieved or that were not successfully assayed) as
previously described (19) (Stata release 9.0, (20)).
All models included the matching factors state (Minnesota vs. Iowa), age at diagnosis
(coded using upper and lower tail-restricted quadratic splines), and proxy status. Covariates
examined were factors associated with NHL in past studies (e.g. alcohol use (21), family
history of hemolymphatic (HLP) cancer (22) and farming (23) as well as demographic
factors (age (24) and education (24-25)). No confounding was evident based a 0.15 or
greater change in the beta coefficient of the main exposure variable when the potential
confounder was removed from the model; therefore, final models included the matching
factors only.
Dose-response was evaluated for pack-years and cigarettes per day based on an informal
examination of point estimates for categorical variables and on trend test p-values derived
by modeling pack-years of smoking and cigarettes per day as continuous variables among
smokers only.
Results
Among 152 successfully assayed cases, 54% or 82 cases were t(14;18)-positive based on
FISH assays. Among 206 successfully assayed cases by IHC, 157 cases were bcl-2-positive
(76%).
Any tobacco use was common in the study population, with only 23% of 1245 controls and
17% of 151 cases with sample successfully assayed with FISH reporting never use of
tobacco products. Any tobacco use was associated with t(14;18)-negative NHL (OR=1.9,
95% CI=1.0 – 3.5) (Table 1). t(14;18)-negative NHL was associated with any cigar use (vs.
no cigar use, OR=1.6, 95% CI=1.0 – 2.6), use of cigarettes only (vs. no tobacco use,
OR=2.0, 95% CI=1.0 – 3.7), use of cigarettes and other tobacco use (vs. no tobacco use,
OR=2.1, 95% CI=1.1 – 3.9), and both current and former smoking (vs. no cigarette use,
OR=1.7, 95% CI 0.9-2.9 and OR= 1.9, 95% CI=1.1-3.2, respectively). Having smoked 40 or
more pack-years (vs. no cigarette use, OR=2.0, 95% CI=1.2 – 3.4), all categories for number
of cigarettes smoked per day, and both age categories for first cigarette use were also
associated with t(14;18)-negative NHL, but neither increasing pack-years of smoking nor
increasing cigarettes per day were associated with the outcome when modeled as a
continuous variables among smokers (p = 0.4 and p = 0.9, respectively).
For t(14;18)-positive NHL, we found that associations with cigarette smoking exposures
were inverse or null (OR's 0.6-1.0), with the strongest inverse association noted for any
cigarette use (vs. no cigarette use, OR=0.6, 95% CI=0.3-1.0). A modest positive association
with t(14;18)-positive NHL was estimated for tobacco use other than cigarette smoking (vs.
no tobacco use, OR=1.6, 95% CI=0.9-2.9). In addition, there was evidence of a stronger
association when chewing tobacco use began before age 18 based on a small number of
exposed cases (OR=2.1, 95% CI=0.9-4.5, 6 exposed cases) than after age 18 (OR=1.2, 95%
CI=0.6-2.3, 7 exposed cases). Case-case effect estimates for t(14;18)-positive vs. t(14;18)-
negative NHL were often below the null for cigarette exposures (Table 1).
No tobacco exposures were clearly associated with either bcl-2 case-subtype. Consistent
with these findings, case-case estimates for bcl-2 positive NHL versus bcl-2 negative NHL
were close to null or very imprecise (Table 2).
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Estimated associations for other non-occupational exposures and t(14;18) case-subtypes
were generally consistent with estimates made for t(14;18) case-subtypes classified based on
PCR (Table 3) (2). Consistent with the PCR results, having a first or second-degree relative
with hemolymphatic cancer was associated with FISH-defined t(14;18)-negative NHL
(OR=3.0, 95% CI=1.8 – 5.0), but not t(14;18)-positive lymphoma (OR=0.9, 95%
CI=0.4-2.3). However, a positive family history was associated with both bcl-2 negative
(OR=2.5, 95% CI=1.2-5.1) and bcl-2 positive (OR=1.6, 95% CI=1.0-2.6) case-subtypes. In
contrast to the PCR results which showed a similarly positive association between hair dye
use and both t(14;18) case-subtypes, FISH results suggest a weaker association between hair
dye use and t(14;18)-positive NHL (OR=1.3, 95% CI=0.6-2.6) than t(14;18)-negative
lymphoma (OR=2.9, 95% CI=1.6-5.0). IHC results suggest a slightly stronger association
between hair dye use and bcl-2 positive NHL (OR=2.2, 95% CI=1.4-3.4), than for bcl-2
negative NHL (OR=1.4, 95% CI=0.5-3.8). However, all estimates were based on small
numbers of exposed cases in each case-subgroup.
Discussion
Using FISH assays, we detected a number of t(14;18)-positive cases that had been
previously classified as t(14;18)-negative based on PCR which has been described
previously (16). Based on the numbers in our previous study and using FISH as the gold
standard, PCR has a sensitivity of 56% and specificity of 88% for detecting t(14;18).
We noted a positive association between FISH-defined t(14;18)-negative NHL and tobacco
use that was not apparent in our previous analysis of t(14;18)-NHL based on PCR assays.
The differences between associations reported for t(14;18) subtypes classified using FISH
and associations previously reported for t(14;18) subtypes classified using PCR may reflect
misclassification of cases by PCR. Differences may also reflect the instability of point
estimates based on small numbers of cases, since the case series classified using the two
approaches were not exactly the same (specifically, 227 cases were included in both studies
and, 11 were included in the PCR study). However, estimated associations with t(14;18)
subtypes classified according to the original PCR assay were comparable to those previously
reported for PCR-based subtypes in this study population (data not shown). Although all
were performed on paraffin-embedded tumor sections, the number of successfully assayed
cases by IHC (n=206) was greater than that for FISH (n=152) or PCR (n=170). These results
are likely to reflect differences in the assays themselves rather than sampling error or sample
quality.
Our findings on smoking were consistent with those of the Nebraska t(14;18)-NHL study
based on tissue microarrays (TMAs) run with FISH (26). They reported an association
between smoking and t(14;18)-negative NHL (OR=1.9, 95% CI=1.1-3.3), but the
association was specific to women with no t(14;18) case-subtype associations evident
among men. The Nebraska study investigators reported that a positive family history of a
hematopoietic cancer was associated with both t(14;18)-subtypes (OR's 1.9-2.2) among both
men and women, while only t(14;18)-negative NHL was associated with family history in
our study. Finally, we found an association between hair-dye use and t(14;18)-negative
NHL, while hair-dye use was not associated with either case-subtype in the Nebraska study.
We noted a higher proportion of t(14;18)-positive cases among all cases (53% vs. 38%) and
among follicular lymphomas (81% vs. 67%) than those in the Nebraska study, which would
be consistent with differences in the prevalence of t(14;18)-NHL between the two study
populations or with reduced sensitivity due to the use of TMAs based on four representative
0.6-mm cores from each biopsy in the Nebraska study.
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The association between cigarette smoking and t(14;18)-negative NHL was unexpected,
given results of several previous studies that found a positive association between smoking
and follicular lymphoma (27-33), which is largely t(14;18)-positive (14-21), as well as prior
evidence of increased t(14;18) in the peripheral blood lymphocytes of smokers compared
with non-smokers (1,34). A previous analysis of tobacco use with all 622 FARM study cases
also showed unclear results. In the entire FARM study population, current smoking was
modestly associated with all lymphoma subtypes (OR=1.5, 95% CI=1.1-2.0), but it was not
more strongly associated with follicular lymphoma (OR=1.4, 95% CI=0.9-2.3) (35).
Overall, bcl-2 expression assays did not clarify the nature of the subtype-specific association
between t(14;18)-negative NHL and cigarette smoking. We did not see evidence of
associations between smoking and bcl-2 negative NHL, which suggests that the associations
observed with t(14;18)-negative NHL were not a function of bcl-2 negative status.
Strengths of the study include use of a large population-based control group (selected
through RDD, Medicare files, and death certificates with a nearly 80% response rate), the
availability of detailed exposure data from both cases and controls, the use of FISH to
determine t(14;18)-subtypes, and the availability of bcl-2 expression data in addition to
information on t(14;18). Among the limitations, cases included in the current analysis were
limited to those with archival tumor material and successful FISH assays, thus less than 25%
of the 622 original FARM study NHL cases were successfully assigned a case-subtype. The
majority of missing cases were from Minnesota (55% of 470 total missing), consequently,
case-subtype:control estimates may have been biased if missing outcome data were
associated with exposures. To address this, we used an EM-based method to impute missing
case-subtype data, as previously described; however, bias due to missing data cannot be
ruled out [20]. Recall bias and misclassification of exposures are potential concerns, but are
not likely to be differential between case-subtypes. Additionally, self-reported smoking is
generally accurate except when considered socially undesirable (i.e. in pregnancy), which
does not apply to this study population (36). Generalizability of the results may be limited
due to the restriction to white, rural males in this study. However, the prevalence of smoking
in the study population was comparable to that of US males in the 1980s. Among controls,
the prevalence of any (past or current) cigarette smoking was 66% overall, 60% in farmers
and 74% in non-farmers. These estimates are comparable, if not lower for farmers, to the
prevalence of any smoking in the same birth cohort of US men in 1980 (70-80%) (37). Thus,
while we cannot rule out the possibility that the findings may have been specific to this
study population, smoking in the study population did not appear to differ substantially from
expectations for a rural population. Finally, uncontrolled confounding is always a
possibility, particularly given that few risk factors for NHL have been identified.
In summary, our data suggest that smoking may be associated with t(14;18)-negative NHL.
In order to clarify the role of smoking and other potential risk factors in the etiology of
t(14;18) NHL, subtypes defined by molecular characteristics in addition to t(14;18) should
be pursued. Future studies should incorporate histologic subtypes assigned in clinical
settings where the role of molecular analyses is increasing in the routine pathologic
evaluation of lymphoma cases (38). Alternatively, improved methods to estimate the
incidence and prevalence of t(14;18) translocations in the peripheral blood lymphocytes of
people without cancer may help clarify whether or how smoking and other exposures
influence the pathogenesis of t(14;18)-positive lymphomas (39-41).
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